Clinical application of next-generation sequencing–based panel to BRAF wild-type advanced melanoma identifies key oncogenic alterations and therapeutic strategies

Changhee Park, Miso Kim, Min Jung Kim, Hyeongmin Kim, Chan Young Ock, Bhumsuk Keam, Tae Min Kim, Dong Wan Kim, Jong Il Kim, Dae Seog Heo

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Molecular profiling with next-generation sequencing (NGS) has been applied in multiple solid cancers to discover potential therapeutic targets. Here, we describe the results of a clinical NGS panel in patients with advanced melanoma. Thirty-six tumor tissues from patients with BRAF wild-type melanoma at Seoul National University Hospital (SNUH; Seoul, Republic of Korea) were collected and deep-sequenced using the SNUH FIRST-Cancer NGS panel to assess single-nucleotide variants, small insertions/deletions, copy number variations, and structural variations to estimate tumor mutation burden (TMB). We discovered 106 oncogenic alterations and most of the patients (n = 33, 92%) harbored at least one oncogenic alteration, including 2 patients who were initially diagnosed as BRAF V600E–negative but were later confirmed to be positive. Altogether, 36 samples were classified into RAS/BRAF/ NF1–mutant (n = 14, 39%) or triple wild-type (n = 22, 61%) melanoma subtypes. The estimated median TMB was 8.2 mutations per Mb, ranging from 0 to 146.67 mutations per Mb. Of the 36 patients, 25 (70%) had actionable alterations with currently developed drugs, and 7 (19.4%) were enrolled in clinical trials with an RAF inhibitor, multiple receptor tyrosine kinase inhibitor, and anti-programmed cell death-1 (PD-1) antibody. TMB tended to associate with progression-free survival (PFS) of treatment with anti-PD-1/PDL-1 antibody (HR, 0.96; 95% confidence interval, 0.92–1.00; P = 0.07). High-TMB (≥13) group was associated with longer PFS than the low-TMB group (median 34.0 vs. 11.0 weeks, P = 0.04). Overall, the clinical use of a NGS panel in patients with advanced melanoma shows association with clinical outcomes and several therapeutic strategies.

Original languageEnglish
Pages (from-to)937-944
Number of pages8
JournalMolecular cancer therapeutics
Volume19
Issue number3
DOIs
StatePublished - 1 Mar 2020

Fingerprint Dive into the research topics of 'Clinical application of next-generation sequencing–based panel to BRAF wild-type advanced melanoma identifies key oncogenic alterations and therapeutic strategies'. Together they form a unique fingerprint.

  • Cite this